Kenvue Inc. $KVUE Stake Raised by Readystate Asset Management LP

Readystate Asset Management LP boosted its holdings in shares of Kenvue Inc. (NYSE:KVUE) by 76.8% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,057,316 shares of the company’s stock after acquiring an additional 459,192 shares during the quarter. Kenvue accounts for about 0.8% of Readystate Asset Management LP’s investment portfolio, making the stock its 26th largest holding. Readystate Asset Management LP’s holdings in Kenvue were worth $18,228,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Arrowstreet Capital Limited Partnership acquired a new stake in shares of Kenvue during the second quarter worth approximately $6,528,000. Jump Financial LLC increased its stake in Kenvue by 210.6% in the 2nd quarter. Jump Financial LLC now owns 54,823 shares of the company’s stock valued at $1,147,000 after buying an additional 37,170 shares during the period. AXA S.A. increased its stake in Kenvue by 21.1% in the 2nd quarter. AXA S.A. now owns 48,892 shares of the company’s stock valued at $1,023,000 after buying an additional 8,524 shares during the period. NewEdge Advisors LLC increased its stake in Kenvue by 219.1% in the 2nd quarter. NewEdge Advisors LLC now owns 97,481 shares of the company’s stock valued at $2,040,000 after buying an additional 66,930 shares during the period. Finally, The Manufacturers Life Insurance Company lifted its position in Kenvue by 0.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 1,873,705 shares of the company’s stock worth $39,217,000 after buying an additional 10,885 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Kenvue Stock Performance

KVUE stock opened at $19.75 on Wednesday. The company has a quick ratio of 0.70, a current ratio of 0.98 and a debt-to-equity ratio of 0.67. The company has a market capitalization of $37.91 billion, a price-to-earnings ratio of 23.23, a P/E/G ratio of 1.48 and a beta of 0.47. Kenvue Inc. has a 12 month low of $14.02 and a 12 month high of $22.44. The firm has a 50 day moving average of $18.47 and a two-hundred day moving average of $17.97.

Kenvue (NYSE:KVUE) last released its quarterly earnings results on Thursday, May 7th. The company reported $0.32 earnings per share for the quarter, beating analysts’ consensus estimates of $0.27 by $0.05. Kenvue had a net margin of 10.61% and a return on equity of 20.81%. The business had revenue of $3.91 billion for the quarter, compared to the consensus estimate of $3.84 billion. During the same quarter last year, the firm earned $0.24 EPS. Kenvue’s revenue for the quarter was up 4.5% on a year-over-year basis. As a group, equities analysts anticipate that Kenvue Inc. will post 1.16 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on KVUE shares. Weiss Ratings upgraded shares of Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, June 15th. UBS Group lifted their price objective on Kenvue from $18.00 to $20.00 and gave the company a “neutral” rating in a research report on Thursday, July 16th. Zacks Research downgraded Kenvue from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 7th. Citigroup dropped their target price on Kenvue from $20.00 to $19.00 and set a “neutral” rating on the stock in a research report on Wednesday, April 15th. Finally, Wall Street Zen raised Kenvue to a “buy” rating in a research note on Sunday, July 12th. Three equities research analysts have rated the stock with a Buy rating and thirteen have issued a Hold rating to the company’s stock. According to data from MarketBeat, Kenvue presently has a consensus rating of “Hold” and a consensus target price of $19.58.

Insider Buying and Selling

In other Kenvue news, General Counsel Matthew Orlando sold 38,491 shares of the firm’s stock in a transaction dated Friday, May 8th. The stock was sold at an average price of $17.66, for a total transaction of $679,751.06. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 1.59% of the stock is owned by insiders.

About Kenvue

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.